Intellia Therapeutics has dosed the first subject in a randomised, placebo-controlled global Phase III trial of its investigational CRISPR-based therapy, NTLA-2002, to treat hereditary angioedema ...

Intellia Therapeutics has commenced subject dosing in the Phase III MAGNITUDE-2 trial of nexiguran ziclumeran (nex-z) for ...

NTLA-2002 is a wholly owned investigational in vivo CRISPR-based therapy in development as a single-dose treatment for this potentially life-threatening d Priority programs – NTLA-2002 for ...

Intellia is developing its wholly owned CRISPR-based pipeline candidate, NTLA-2002, for the treatment of hereditary angioedema (“HAE”). The pivotal phase III HAELO study is actively enrolling ...

Analysts at William Blair issued their Q1 2026 earnings estimates for shares of Intellia Therapeutics in a research report ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by ...

Their lead therapies, like NTLA-2002 for HAE and NTLA-2001 for ATTR, aim to offer curative, single-dose treatments, potentially disrupting multi-billion dollar markets. The company is also ...